Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
bluebird bio, Inc. (BLUE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress – Continued strong commercial launch for ZYNTEGLO® and SKYSONA®&#59; 16 patient starts across both programs to date –"
05/09/2023 8-K Quarterly results
Docs: "bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress – Biologics License Application for lovo-cel for sickle cell disease submitted to FDA –"
11/07/2022 8-K Quarterly results
Docs: "EMPLOYMENT AGREEMENT",
"– Commercial launch of ZYNTEGLO® underway&#59; on track for first apheresis in the fourth quarter of 2022 – – Chris Krawtschuk appointed chief financial officer –"
08/04/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/05/2021 8-K Quarterly results
Docs: "bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress – Company separation completed on November 4, 2021 –"
05/05/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress - Company to host conference call today, November 4, 2020 at 4:30PM ET -"
08/05/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress – Received EU conditional marketing authorization for ZYNTEGLO ® gene therapy for patients 12 years and older with transfusion dependent β-thalassemia who do not have a β 0 /β 0 genotype –"
11/01/2018 8-K Quarterly results
Docs: "bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress – Company plans to pursue accelerated development pathway for LentiGlobin TM in sickle cell disease –"
08/02/2018 8-K Quarterly results
Docs: "bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress - Lenti-D™ granted Priority Medicines designation from European Medicines Agency and Breakthrough Designation from U.S. Food and Drug Administration in cerebral adrenoleukodystrophy –"
05/02/2018 8-K Quarterly results
Docs: "bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress – Completed Northstar study of LentiGlobin in transfusion dependent β‑thalassemia –"
11/01/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
05/03/2017 8-K Form 8-K - Current report
11/02/2016 8-K Quarterly results
Docs: "PHASE 3 HGB-207 STUDY OF LENTIGLOBIN OPENED – In September, bluebird bio opened the company’s first Phase 3 study of LentiGlobin drug product. HGB-207 is a global, multi-center study in patients with TDT with non-β0/β0 genotypes. This study will incorporate the addition of bluebird bio’s transduction enhancers to the drug product manufacturing process, and will be conducted under the same Investigational New Drug application as previous studies of LentiGlobin drug product in TDT. This study, which will include adult and adolescent patients and pediatric patients , is intended to be pivotal in the U.S. and confirmatory in the E.U. bluebird bio plans to initiate the HGB‑212 pivotal study of LentiGlobin drug product in patients with TDT with β0/β0 genotypes in 2017. ..."
08/03/2016 8-K Form 8-K - Current report
05/04/2016 8-K Quarterly results
Docs: "bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress – Presented interim clinical data from Starbeam study of Lenti-D TM in cerebral adrenoleukodystrophy at American Academy of Neurology Annual Meeting –"
11/04/2015 8-K Quarterly results
Docs: "bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress"
08/06/2015 8-K Quarterly results
Docs: "bluebird bio Reports Second Quarter 2015 Financial Results and Recent Operational Progress"
05/06/2015 8-K Quarterly results
Docs: "NEWS RELEASE"
03/05/2014 8-K Quarterly results
Docs: "bluebird bio Reports Fiscal Year End 2013 Financial Results CAMBRIDGE, MA, March 5, 2014 - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013. At fiscal year end bluebird bio held $206.3 million in cash and cash equivalents. Pipeline Update and 2013 Highlights Lenti-D"
11/14/2013 8-K Quarterly results
Docs: "bluebird bio Reports Fiscal Third Quarter 2013 Financial Results CAMBRIDGE, MA, November 14, 2013 - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2013. Financial Results Revenues were $6.4 million during the quarter ended September 30, 2013 compared to $0.1 million for the quarter ended September 30, 2012 and include amounts allocated to research and development services from the Celgene collaboration. Net cash provided by operating activities during the nine months ended September 30, 2013 was $48.9 million. bluebird bio held $216.8 million in cash and cash equivalents as of September 30, 2..."
08/14/2013 8-K Quarterly results
Docs: "bluebird bio Reports Fiscal Second Quarter 2013 Financial Results CAMBRIDGE, MA, August 14, 2013 - bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2013. Financial Results Revenues were $6.3 million during the quarter ended June 30, 2013 compared to $0.1 million for the quarter ended June 30, 2012 and include amounts allocated to research and development services from the Celgene collaboration. Net cash provided by operating activities during the six months ended June 30, 2013 was $57.8 million. bluebird bio held $228.8 million in cash and cash equivalents as of June 30, 2013. Total operating expens..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy